Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus

Cancer Research

Volumn 60, Issue 11, 2000, Pages 2790-2795

  Pawlik, Timothy M ^a   Nakamura, Hideo ^a   Yoon, Sam S ^a   Mullen, John T ^a   Chandrasekhar, Soundararajalu ^a   Chiocca, E Antonio ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TRANSGENE; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; GANCICLOVIR; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HERPESVIRUS 1, HUMAN; HUMANS; LIVER; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; PRODRUGS; RATS; TRANSGENES; TUMOR CELLS, CULTURED; VERO CELLS;

EID: 0034212631     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Esquivel, C. O., Keeffe, E. B., Garcia, G., Imperial, J. C., Millan, M. T., Monge, H., and So, S. K. Resection versus transplantation for hepatocellular carcinoma. J. Gastroenterol. Hepatol., 14 (Suppl.): S37-S41, 1999.
2. Stuart, K. E., Anand, A. J., and Jenkins, R. L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer (Phila.), 77: 2217-2222, 1996.
3. Schafer, D. F., and Sorrell, M. F. Hepatocellular carcinoma. Lancet, 353: 1253-1257, 1999.
4. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
5. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J. L., and Klatzmann, D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90: 7024-7028, 1993.
6. Tung, C., Federoff, H. J., Brownlee, M., Karpoff, H., Weigel, T., Brennan, M. F. and Fong, Y. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum. Gene Ther., 7: 2217-2224, 1996.
7. Chen, S. H., Chen, X. H., Wang, Y., Kosai, K., Finegold, M. J., Rich, S. S., and Woo, S. L. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA, 92: 2577-2581, 1995.
8. Karpoff, H. M., D'Angelica, M., Blair, S., Brownlee, M. D., Federoff, H., and Fong, Y. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and γ-interferon. J. Clin. Invest., 99: 799-804, 1997.
9. Spaete, R. R., and Frenkel, N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell, 30: 295-304, 1982.
10. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
11. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC), 252: 854-856, 1991
12. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. Reovirus therapy of tumors with activated Ras pathway. Science (Washington DC), 282: 1332-1334, 1998.
13. Sinkovics, J. G., and Horvath, J. C. Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol., 16: 1-15, 2000.
14. Boviatsis, E. J., Park, J. S., Sena-Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M. X., Breakefield, X. O., and Chiocca, E. A. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res., 54: 5745-5751, 1994.
15. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., I: 938-943, 1995.
16. Pyles, R. B., Warnick, R. E., Chalk, C. L., Szanti, B. E., and Parysek, L. M. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther., 8: 533-544, 1997.
17. Chase, M., Chung, R. Y., and Chiocca, E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol., 16: 444-448, 1998.
18. Clarke, L., and Waxman, D. J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res., 49: 2344-2350, 1989.
19. Li, A. P., Roque, M. A., Beck, D. J., and Kaminiski, D. L. Isolation and culturing of hepatocytes from human livers. J. Tissue Culture Methods, 14: 139-142. 1992.
20. Yoon, S. S., Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann. Surg., 228: 366-374, 1998.
21. Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., and Breakefield, X. O. Therapeutic efficiency and safety of a second-generation replication-conditional HSV-1 vector for brain tumor gene therapy. Hum. Gene Ther., 8: 2057-2068, 1997.
22. Carroll, N. M., Chiocca, E. A., Takahashi, K., and Tanabe, K. K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg., 224: 323-330, 1996.
23. Aghi, M., Chou, T. C., Suling, K., Breakefield, X. O., and Chiocca, E. A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res., 59: 3861-3865, 1999.
24. Carroll, N. M., Chase, M., Chiocca, E. A., and Tanabe, K. K. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res., 69: 413-417, 1997.
25. Elford, H. L., Freese, M., Passamani, E., and Morris, H. P. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem., 245: 5228-5233, 1970.
26. Madariaga, J. R., Subbotin, V. M., Lopez, S. R., Sahin, M., Ferres, J., Dvorchik, I., Subotin, M. V., Wang, Z., Nalesnik, M. A., Carr, B. I., Valdivia, L. A., Rao, A. S., and Fung, J. J. Quantitative assessment of the development of hepatoma in a buffalo rat model. Transplant Proc., 29: 2263-2264, 1997.
27. Yoon, S. S., Nakamura, H., Carroll, N. M., Bode, B. P., Chiocca, E. A., and Tanabe, K. K. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J., 14: 301-311, 2000.
28. Kooby, D. A., Carew, J. F., Halterman, M. W., Mack, J. E., Bertino, J. R., Blumgart, L. H., Federoff, H. J., and Fong, Y. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J., 13 1325-1334, 1999.
29. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner. M., and zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
30. Kaufman, D., and Chabner, B. A. Clinical strategies for cancer treatment: the role of drugs. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 1-16. Philadelphia: Lippincott-Raven, 1996.
31. Advani, S. J., Sibley, G. S., Song, P. Y., Hallahan, D. E., Kataoka, Y., Roizman, B., and Weichselbaum. R. R. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther., 5: 160-165, 1998.
32. Advani, S. J., Chung, S. M., Yan, S. Y., Gillespie, G. Y., Markert J. M., Whitley, R. J., Roizman, B., and Weichselbaum, R. R. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res., 59: 2055-2058, 1999.
33. Colvin, O. M. Alkylating agents and platinum compounds. In: J. F. Holland, E. Frei, R. C. Bast, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, pp. 733-734. Philadelphia: Lea and Fabiger, 1993.
34. Meignier, B., Martin, B., Whitley, R. J., and Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis., 162: 313-321, 1990.
35. Hunter, W. D., Martuza, R. L., Feigenbaum, F., Todo, T., Mineta, T., Yazaki, T., Toda, M., Newsome, J. T., Platenberg, R. C., Manz, H. J., and Rabkin, S. D. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol., 73: 6319-6326, 1999.